treatment of wm must be targeted at the underlying lymphocellular malignancy , but amelioration of the hyperviscous state and component transfusion ( s ) to correct abnormal coagulation parameters will decrease the incidence of bleeding .
C0024419
wm
C0221104
hyperviscous